Free Trial
OTCMKTS:AGNPF

Algernon Pharmaceuticals (AGNPF) Stock Price, News & Analysis

Algernon Pharmaceuticals logo
$0.06 -0.01 (-9.31%)
As of 05/28/2025 01:24 PM Eastern

About Algernon Pharmaceuticals Stock (OTCMKTS:AGNPF)

Key Stats

Today's Range
$0.06
$0.06
50-Day Range
$0.05
$0.07
52-Week Range
$0.04
$0.12
Volume
2,204 shs
Average Volume
17,271 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, pancreatic and small cell lung cancer, and acute lung injury in Canada and Australia. The company's pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries. The company was formerly known as Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.

Receive AGNPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Algernon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AGNPF Stock News Headlines

Algernon Announces $1M Private Placement
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
See More Headlines

AGNPF Stock Analysis - Frequently Asked Questions

Algernon Pharmaceuticals' stock was trading at $0.0463 at the start of the year. Since then, AGNPF stock has increased by 22.0% and is now trading at $0.0565.
View the best growth stocks for 2025 here
.

Shares of Algernon Pharmaceuticals split on the morning of Friday, March 3rd 2023. The 4-1 split was announced on Friday, March 3rd 2023. The newly issued shares were distributed to shareholders after the closing bell on Friday, March 3rd 2023. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

Shares of AGNPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
5/28/2025
Next Earnings (Estimated)
7/28/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:AGNPF
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (OTCMKTS:AGNPF) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners